On March 30, 2026, Jasper Therapeutics, Inc. (Nasdaq: JSPR) announced its financial results for the fourth quarter and the year ended December 31, 2025. The company reported a net loss of $9.1 million for the fourth quarter and a total net loss of $75.8 million for the full year. The earnings per share were reported at $0.32 for the fourth quarter and $3.95 for the year. As of December 31, 2025, Jasper had cash and cash equivalents totaling $28.7 million. The company highlighted significant progress in its clinical trials for briquilimab, a novel antibody therapy targeting c-Kit (CD117) for mast cell-driven diseases. CEO Jeet Mahal expressed optimism about the ongoing studies, particularly the BEACON study, which showed promising results in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). The company is finalizing dose selection for the Phase 2b portion of its planned Phase 2b/3 study in CSU, with patient enrollment expected to commence in the second half of 2026, pending capital availability. Jasper's leadership change, with Jeet Mahal appointed as CEO, is seen as a strategic move to drive the next phase of clinical growth. The company remains focused on advancing briquilimab's development while navigating its financial challenges.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.